Tuesday, November 17, 2026

Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone

Figueroa, F.; Salinas, L.; Montgomery-Bowie, C.B.; Sellers, R.; Sims, L.; Cox, G.P.; Golove, S.L.; Thai, P.N.; Chiamvimonvat, N.; Cortopassi, G.; et al. Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone. Antioxidants 2026, 15, 1490. doi:10.3390/antiox15111490 

 DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.